A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Inclusion Criteria:

• Male and/or female subjects between ≥18 and ≤75 years of age inclusive.

• Diagnosis of moderate to severe active Lupus.

• Receiving a stable dose of methotrexate, azathioprine, leflunomide, mizoribine,mycophenolate/mycophenolic acid, anti-malarials or corticosteroids.

Exclusion Criteria:

• Active renal lupus

• Severe active central nervous system (CNS) lupus

• Have cancer or a history of cancer within 5 years of screening.

• Have a history of thrombosis (venous or arterial) or other vascular complicationswithin the last 6 months, or any history of either recurrent thrombosis or apulmonary embolus.

• Active bacterial, viral, fungal, mycobacterial or other infections

• Psychiatric condition including recent or active suicidal ideation or behavior

• Have active fibromyalgia/myofascial/chronic pain.

• Pregnant female subjects; breastfeeding female subjects; females subjects planningto become pregnant during the study; fertile male subjects and WOCBP who areunwilling or unable to use a highly effective method of contraception.